Cargando…
Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436305/ https://www.ncbi.nlm.nih.gov/pubmed/33908311 http://dx.doi.org/10.1177/02698811211000773 |
| _version_ | 1783751974301204480 |
|---|---|
| author | Papanastasiou, Evangelos Shergill, Sukhwinder S |
| author_facet | Papanastasiou, Evangelos Shergill, Sukhwinder S |
| author_sort | Papanastasiou, Evangelos |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8436305 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84363052021-09-14 Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)? Papanastasiou, Evangelos Shergill, Sukhwinder S J Psychopharmacol Letters to the Editor SAGE Publications 2021-04-28 2021-09 /pmc/articles/PMC8436305/ /pubmed/33908311 http://dx.doi.org/10.1177/02698811211000773 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Letters to the Editor Papanastasiou, Evangelos Shergill, Sukhwinder S Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)? |
| title | Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)? |
| title_full | Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)? |
| title_fullStr | Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)? |
| title_full_unstemmed | Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)? |
| title_short | Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)? |
| title_sort | why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fmri)? |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436305/ https://www.ncbi.nlm.nih.gov/pubmed/33908311 http://dx.doi.org/10.1177/02698811211000773 |
| work_keys_str_mv | AT papanastasiouevangelos whyshouldpharmacologicaltrialsinschizophreniaemployfunctionalmagneticresonanceimagingfmri AT shergillsukhwinders whyshouldpharmacologicaltrialsinschizophreniaemployfunctionalmagneticresonanceimagingfmri |